Current Report Filing (8-k)
July 11 2014 - 5:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): July 11, 2014
ROCK CREEK PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
(State or other jurisdiction of incorporation) |
000-15324
(Commission File Number) |
52-1402131
(IRS Employer Identification No.) |
|
|
|
|
2040 Whitfield Avenue, Suite 300
Sarasota, Florida 34243
(Address of principal executive offices,
including zip code)
(804) 527-1970
(Registrant’s telephone number,
including area code) |
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Attached as Exhibit 99.1 to this Current
Report on Form 8-K is a press release issued by Rock Creek Pharmaceuticals, Inc. on July 11, 2014.
| Item 9.01. | Financial Statements and Exhibits. |
| 99.1 | Press release, dated July
11, 2014. |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ROCK CREEK PHARMACEUTICALS, INC. |
|
|
|
|
|
By: |
/s/ Michael J. Mullan |
|
|
Michael J. Mullan Chairman of the Board and Chief Executive Officer |
Date: July 11, 2014
Exhibit 99.1
Rock Creek
Pharmaceuticals Issues Update On
US Investigational
New Drug Application
Sarasota, FL. July 11, 2014 /PRNewswire/
Rock Creek Pharmaceuticals, Inc. (NASDAQ: RCPI), an emerging biotechnology company, today announced that the Food and Drug Administration
(“FDA”), has notified the Company that the agency will provide comments on RCP’s Investigational New Drug (“IND”)
application before granting the Company permission to start its clinical trial in the US.
Dr. Chris Chapman, RCP’s President, commented, “We
appreciate the agency’s review and comments on our IND. When we receive the agency’s official comments and/or recommendations,
we will respond expeditiously. We look forward to moving this important product through the regulatory process.”
Certain statements contained in this release constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited
to statements identified by words such as "believes," "expects," "anticipates," "estimates,"
"intends," "plans," "targets," "projects" and similar expressions. The statements in this
release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and
uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or
contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges
inherent in new product development initiatives, including the continued development and market acceptance of our nutraceutical
dietary supplements products, the effect of any competitive products, our ability to license and protect our intellectual property,
our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy
and/or regulation, potential litigation by or against us, any governmental review of our products or practices and the outcome
of the ongoing investigations as well as other risks discussed from time to time in our filings with the Securities and Exchange
Commission, including, without limitation, our annual report on Form 10-K for the fiscal year ended December 31, 2013 filed on
March 17, 2014. We undertake no duty to update any forward-looking statement or any information contained in this press release
or in other public disclosures at any time.
About Rock Creek Pharmaceuticals, Inc.
Rock
Creek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of new drugs,
formulations and compounds that provide therapies for inflammatory conditions, clinical immunology, neurological disease and behavioral
health. Additionally, through its subsidiary RCP Development, the Company is engaged in the manufacturing and sale of nutraceutical
dietary supplements designed to promote maintenance of a healthy metabolism and lifestyle.
For more information, visit: http://www.rockcreekpharma.com
CONTACT:
Ted Jenkins
Vice President, Corporate Strategy, Development, Investor Relations
Rock Creek Pharmaceuticals
tjenkins@rockcreekpharma.com
Rock Creek Pharmaceuticals (CE) (USOTC:RCPIQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rock Creek Pharmaceuticals (CE) (USOTC:RCPIQ)
Historical Stock Chart
From Apr 2023 to Apr 2024